01 / Contract Profile
HHSO100201600038C Federal Contract Award
Agency code 7505
THE PURPOSE OF THIS MODIFICATION IS ADD SUPPLEMENTAL FUNDING FOR 0002 AND TO UPDATED THE PERIOD OF PERFORMANCE (POP) FOR CLIN 0001 TO END ON 12/31/2028.
02 / Contract Size and Status
What is the recorded size and timing of this contract?
03 / Spending Trend
HHSO100201600038C contract spending by fiscal year
Annual net obligations across the complete period available for this agency and PIID, from the first recorded fiscal year through the latest contract action.
| Fiscal year | Net obligations | Actions | Change |
|---|---|---|---|
| FY 2016 | $35.17M | 1 | — |
| FY 2018 | $77.99M | 1 | +121.7% |
| FY 2019 | $0 | 2 | −100.0% |
| FY 2020 | $0 | 2 | — |
| FY 2022 | $808.1K | 3 | — |
| FY 2023 | $2.00M | 2 | +147.5% |
| FY 2024 | $12.27M | 2 | +513.6% |
| FY 2025 | $47.50M | 4 | +287.1% |
| FY 2026 | $8.10M | 1 | −82.9% |
04 / Federal Buyer
Which organization manages this contract?
| Department | Contracting agency | Contracting office |
|---|---|---|
| HEALTH AND HUMAN SERVICES, DEPARTMENT OF | OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE | BARDA - ASPR / DAAPPO / BARDA DCMA |
05 / Contractor
Who holds this federal contract?
UEI J28SZXJLMNB8 · CAGE 04493
06 / NAICS Industries
Which industries classify this contract?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| 541711 | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY | $183.84M | 18 | 100.0% |
07 / Products and Services
What products or services were purchased?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| AN13 | HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT | $183.84M | 18 | 100.0% |
08 / Place of Performance
Where is the work recorded?
ZIP 074249999
09 / Contract Actions
What modifications and obligations were recorded?
| Signed date | Modification | Obligation | Contracting office | NAICS | PSC |
|---|---|---|---|---|---|
| Aug 10, 2026 | P00017 | $8.10M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541711 | AN13 |
| Sep 25, 2025 | P00016 | $13.75M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541711 | AN13 |
| Jun 24, 2025 | P00015 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541711 | AN13 |
| May 1, 2025 | P00014 | $4.65M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541711 | AN13 |
| Feb 14, 2025 | P00013 | $29.10M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541711 | AN13 |
| Jul 29, 2024 | P00012 | $3.00M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541711 | AN13 |
| May 24, 2024 | P00011 | $9.27M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541711 | AN13 |
| Jul 26, 2023 | P00010 | $2.00M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541711 | AN13 |
| Apr 13, 2023 | P00009 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541711 | AN13 |
| Sep 27, 2022 | P00008 | -$2.35M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541711 | AN13 |
| Aug 31, 2022 | P00007 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541711 | AN13 |
| Jun 1, 2022 | P00006 | $3.16M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541711 | AN13 |
| Oct 29, 2020 | P00005 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541711 | AN13 |
| Feb 21, 2020 | P00004 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541711 | AN13 |
| Jul 26, 2019 | P00003 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541711 | AN13 |
10 / Reading the Contract
How should this award record be interpreted?
Read the PIID as a transaction history, not as a single purchase price. Net obligations combine the base action with later increases, reductions, corrections, and deobligations recorded under the same contract.
Verify the buyer
Agency and office identify who manages the procurement relationship.
Follow modifications
Each action can change funding, scope, dates, or administrative terms.
Compare the market
Use NAICS, PSC, and the contractor profile to identify related buyers and competitors.